BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that several patients have been treated with its Survivin antagonist. The U.S. Food and Drug Administration (FDA) recently accepted the Company’s Investigational New Drug (IND) application for the use of its Survivin antagonist.
